| 前收市價 | 4.6200 |
| 開市 | 4.6200 |
| 買盤 | 0.0000 x 無 |
| 賣出價 | 0.0000 x 無 |
| 今日波幅 | 4.6800 - 4.7400 |
| 52 週波幅 | 1.9700 - 7.4400 |
| 成交量 | |
| 平均成交量 | 26 |
| 市值 | 125.573M |
| Beta 值 (5 年，每月) | 1.78 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.4200 |
| 業績公佈日 | 2024年5月08日 - 2024年5月13日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 無 |
ZacksThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
ZacksSyros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.
ZacksSyros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
